Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

Blood

Volumn 113, Issue 14, 2009, Pages 3383-3391

  Rotta, Marcello ^a   Storer, Barry E ^a,b   Sahebi, Firoozeh ^c   Shizuru, Judith A ^d   Bruno, Benedetto ^e   Lange, Thoralf ^f   Agura, Edward D ^g   McSweeney, Peter A ^h   Pulsipher, Michael A ⁱ   Hari, Parameswaran ^j   Maziarz, Richard T ^k   Chauncey, Thomas R ^l   Appelbaum, Frederick R ^a,b   Sorror, Mohamed L ^a   Bensinger, William ^a,b   Sandmaier, Brenda M ^a,b   Storb, Rainer F ^a,b   Maloney, David G ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g BAYLOR UNIVERSITY   (United States)

^h Rocky Mountain Cancer Center   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PENTOSTATIN; TACROLIMUS;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; FAILURE TO THRIVE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HALLUCINATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NEUTROPHILIA; OVERALL SURVIVAL; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REMISSION; SEIZURE; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; STUPOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREMOR; VIRUS PNEUMONIA; VIRUS REACTIVATION; VOMITING; WHOLE BODY RADIATION;

EID: 65149104407     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-170746     Document Type: Article

References (49)

1. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwen-huis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet. 1996;347:800-801.
2. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.
3. Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. Graft-versus-myeloma effect [letter]. Lancet. 1996;348:346.
4. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
5. Björkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma-a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711-4718.
6. BensingerWI, Buckner CD, Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. He-matol Oncol Clin North Am. 1997;11:147-157.
7. Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209-216.
8. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936.
9. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109: 3588-3594.
10. Maloney DG, Molina AJ, Sahebi F, et al. Allograft-ing with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102: 3447-3454.
11. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autolo-gous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002; 100:755-760.
12. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
13. Sorror ML, Maris MB, Storb R, et al. Hematopoi-etic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919.
14. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeu-tic Agents. New York: Columbia University Press; 1949:191.
15. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-2030.
16. Bryant E, Martin PJ. Documentation of engraft-ment and characterization of chimerism following hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hema-topoietic Cell Transplantation. Oxford, UK: Black-well Publishing Ltd; 2004:234-243.
17. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
20. Pepe MS, Longton G, Thornquist M. Aqualifier Q for the survival function to describe the prevalence of a transient condition. Stat Med. 1991;10: 413-421.
21. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin On-col. 2005;23:9227-9233.
22. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883.
23. Attal M, Harousseau JL, Stoppa AM, et al. A pro-spective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
24. Fermand JP, Marolleau JP, Alberti C, et al. In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [abstract]. Blood. 2001;98:815a.
25. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349:2495-2502.
26. Sonneveld P, van der Holt B, VellengaE, et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial [abstract]. Blood. 2005;106:715a.
27. Goldschmidt H. Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica. 2005;90(suppl 1):38.
28. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-2441.
29. Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112:3115-3121.
30. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140:625-634.
31. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474-3480.
32. Bruno B, RottaM, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-1120.
33. RosinolL,Pérez-Simón JA, Sureda A, et al. A prospective PETHEMAstudy of tandem autolo-gous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591-3593.
34. Turesson I, Abildgaard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol. 1999;106:1005-1012.
35. Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997;97:29-37.
36. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
37. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008;111:4039-4047.
38. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93:560-565.
39. Anagnostopoulos A, Gika D, Hamilos G, et al. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. Leuk Lymphoma. 2004;45:2275-2279.
40. Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22:1250-1255.
41. Sorror M, Storer B, Sandmaier BM, et al. Hema-topoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992-2001.
42. Sala-Torra O, Martin PJ, Storer B, et al. Serious or chronic graft-versus-host disease after hema-topoietic cell transplantation: a comparison of my-eloablative and non-myeloablative conditioning regimens. Bone MarrowTransplant. 2008;41:887-893.
43. van de Donk NW, Kröger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloab-lative allogeneic stem cell transplantation in multiple myeloma. Blood. 2006;107:3415-3416.
44. Bruno B, Patriarca F, Sorasio R, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica. 2006;91:837-839.
45. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficacy of bort-ezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica. 2005; 90:278-279.
46. El-Cheikh J, Michallet M, Nagler A, et al. HIgh response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93:455-458.
47. Kröger N, Zabelina T, Ayuk F, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol. 2006; 34:770-775.
48. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the pro-teasome inhibitor bortezomib [erratum appears in Proc Natl Acad Sci USA. 2004;101:12777]. Proc Natl Acad Sci USA. 2004;101:8120-8125.
49. Hallett WH, Ames E, Motarjemi M, et al. Sensiti-zation of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008;180:163-170.